This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2023 Sep 2;402(10404):771-772.

doi: 10.1016/S0140-6736(23)01414-9.

Bold moves for vaccine manufacturing equity

Ole Kristian Aars¹, Nina Schwalbe²

Affiliations

Affiliations

¹ University of Oslo, Institute of Health and Society, Oslo, Norway.
² Heilbrunn Department of Population and Family Health, Mailman School of Public Health, New York, NY 10032, USA; UN University, International Institute for Global Health, Kuala Lumpur, Malaysia; University of the Witwatersrand, Johannesburg, South Africa. Electronic address: nschwalbe@ssc.nyc.

PMID: 37659773
DOI: 10.1016/S0140-6736(23)01414-9

Bold moves for vaccine manufacturing equity

Ole Kristian Aars et al. Lancet. 2023.

. 2023 Sep 2;402(10404):771-772.

doi: 10.1016/S0140-6736(23)01414-9.

Authors

Ole Kristian Aars¹, Nina Schwalbe²

Affiliations

¹ University of Oslo, Institute of Health and Society, Oslo, Norway.
² Heilbrunn Department of Population and Family Health, Mailman School of Public Health, New York, NY 10032, USA; UN University, International Institute for Global Health, Kuala Lumpur, Malaysia; University of the Witwatersrand, Johannesburg, South Africa. Electronic address: nschwalbe@ssc.nyc.

PMID: 37659773
DOI: 10.1016/S0140-6736(23)01414-9

No abstract available

PubMed Disclaimer

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science